In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis

Overview

Journal Korean J Parasitol

Specialty Parasitology

Date 2016 May 17

PMID 27180573

Citations 5

Authors

Seon-Ju Yeo

Chunmei Jin

Sungyeon Kim

Hyun Park

Affiliations

Soon will be listed here.

Abstract

Toxoplasma gondii is an important opportunistic pathogen that causes toxoplasmosis, which has very few therapeutic treatment options. The most effective therapy is a combination of pyrimethamine and sulfadiazine; however, their utility is limited because of drug toxicity and serious side effects. For these reasons, new drugs with lower toxicity are urgently needed. In this study, the compound, (Z)-1-[(5-nitrofuran-2-yl)methyleneamino]-imidazolidine-2,4-dione (nitrofurantoin), showed anti-T. gondii effects in vitro and in vivo. In HeLa cells, the selectivity of nitrofurantoin was 2.3, which was greater than that of pyrimethamine (0.9). In T. gondii-infected female ICR mice, the inhibition rate of T. gondii growth in the peritoneal cavity was 44.7% compared to the negative control group after 4-day treatment with 100 mg/kg of nitrofurantoin. In addition, hematology indicators showed that T. gondii infection-induced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, biochemical parameters involved in liver injury, were reduced by nitrofurantoin significantly. Moreover, nitrofurantoin exerted significant effects on the index of antioxidant status, i.e., malondialdehyde (MDA) and glutathione (GSH). The nitrofurantoin-treated group inhibited the T. gondii-induced MDA levels while alleviating the decrease in GSH levels. Thus, nitrofurantoin is a potential anti-T. gondii candidate for clinical application.

Citing Articles

The Brazilian Toxoplasma gondii strain BRI caused greater inflammation and impairment in anxiogenic behavior in mice, which was reverted by rosuvastatin treatment.

Evangelista F, de Laet SantAna P, Ferreira W, Ferreira T, Dos Santos M, de Souza A Parasitol Res. 2023; 123(1):64.

PMID: 38117414 DOI: 10.1007/s00436-023-08038-4.

Evaluation of mono and combined nitrofurantoin therapy for toxoplasmosis using murine model.

Elkholy A, Wassef R, Alsaid O, Elawady M, Barakat A, Soror A Pathog Glob Health. 2023; 117(7):664-673.

PMID: 37032491 PMC: 10498811. DOI: 10.1080/20477724.2023.2200577.

Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites.

Sanchez-Sanchez R, Ferre I, Re M, Vazquez P, Ferrer L, Blanco-Murcia J Int J Parasitol Drugs Drug Resist. 2018; 8(1):112-124.

PMID: 29501973 PMC: 6114101. DOI: 10.1016/j.ijpddr.2018.02.003.

A Systematic Review of and Activities of Anti Drugs and Compounds (2006-2016).

Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E, Daryani A Front Microbiol. 2017; 8:25.

PMID: 28163699 PMC: 5247447. DOI: 10.3389/fmicb.2017.00025.

Lectins from (ScLL) and (ArtinM) Are Able to Induce Beneficial Immunomodulatory Effects in a Murine Model for Treatment of Infection.

Ramos E, Santana S, Silva M, Santiago F, Mineo T, Mineo J Front Cell Infect Microbiol. 2016; 6:164.

PMID: 27933277 PMC: 5122570. DOI: 10.3389/fcimb.2016.00164.

References

EYLES D, Coleman N . The effect of metabolites on the antitoxoplasmic action of pyrimethamine and sulfadiazine. Am J Trop Med Hyg. 1960; 9:277-83. DOI: 10.4269/ajtmh.1960.9.277. View

Derouin F, Piketty C, Chastang C, Chau F, Rouveix B, Pocidalo J . Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob Agents Chemother. 1991; 35(2):252-5. PMC: 244986. DOI: 10.1128/AAC.35.2.252. View

Muccioli G, Fazio N, Scriba G, Poppitz W, Cannata F, Poupaert J . Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. J Med Chem. 2006; 49(1):417-25. DOI: 10.1021/jm050977k. View

Yarim G, Nisbet C, Oncel T, Cenesiz S, Ciftci G . Serum protein alterations in dogs naturally infected with Toxoplasma gondii. Parasitol Res. 2007; 101(5):1197-202. DOI: 10.1007/s00436-007-0601-0. View

Sabin A, Feldman H . Chorioretinopathy associated with other evidence of cerebral damage in childhood; a syndrome of unknown etiology separable from congenital toxoplasmosis. J Pediatr. 1949; 35(3):296-309. DOI: 10.1016/s0022-3476(49)80002-3. View

Dubey J, Velmurugan G, Ulrich V, Gill J, Carstensen M, Sundar N . Transplacental toxoplasmosis in naturally-infected white-tailed deer: Isolation and genetic characterisation of Toxoplasma gondii from foetuses of different gestational ages. Int J Parasitol. 2008; 38(8-9):1057-63. DOI: 10.1016/j.ijpara.2007.11.010. View

Jiang J, Jin C, Kim Y, Kim H, Park W, Park H . Anti-toxoplasmosis effects of oleuropein isolated from Fraxinus rhychophylla. Biol Pharm Bull. 2008; 31(12):2273-6. DOI: 10.1248/bpb.31.2273. View

Piketty C, Derouin F, Rouveix B, Pocidalo J . In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother. 1990; 34(8):1467-72. PMC: 171854. DOI: 10.1128/AAC.34.8.1467. View

Zejc A, Kiec-Kononowicz K, Chlon G, Kleinrok Z, Kolasa K, Pietrasiewicz T . Synthesis and pharmacological properties of diphenylimidazolidine acetic and propionic acids derivatives. Pol J Pharmacol Pharm. 1989; 41(5):483-93. View

10.

Dannemann B, McCutchan J, Israelski D, Antoniskis D, Leport C, Luft B . Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992; 116(1):33-43. DOI: 10.7326/0003-4819-116-1-33. View

11.

Luft B, Remington J . Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992; 15(2):211-22. DOI: 10.1093/clinids/15.2.211. View

12.

Roca B, Calabuig C, Arenas M . [Toxoplasmosis and hepatitis]. Med Clin (Barc). 1992; 99(15):595-6. View

13.

Georgiev V . Management of toxoplasmosis. Drugs. 1994; 48(2):179-88. DOI: 10.2165/00003495-199448020-00005. View

14.

Kiec-Kononowicz K, Byrtus H, Zejc A, Filipek B, Chevallet P . Synthesis and antiarrhythmic properties of basic amide derivatives of imidazolidine-2,4-dione and pyrrolidine-2,5-dione II. Farmaco. 1995; 50(5):355-60. View

15.

Niwata S, Fukami H, Sumida M, Ito A, Kakutani S, Saitoh M . Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. J Med Chem. 1997; 40(14):2156-63. DOI: 10.1021/jm960793t. View

16.

REITMAN S, Frankel S . A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957; 28(1):56-63. DOI: 10.1093/ajcp/28.1.56. View

17.

GARIN J, EYLES D . [Spiramycin therapy of experimental toxoplasmosis in mice]. Presse Med (1893). 1958; 66(42):957-8. View

18.

Jin C, Kaewintajuk K, Jiang J, Jeong W, Kamata M, Kim H . Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro. Exp Parasitol. 2008; 121(2):132-6. DOI: 10.1016/j.exppara.2008.10.006. View

19.

Karaman U, Celik T, Raika Kiran T, Colak C, Daldal N . Malondialdehyde, glutathione, and nitric oxide levels in Toxoplasma gondii seropositive patients. Korean J Parasitol. 2009; 46(4):293-5. PMC: 2612619. DOI: 10.3347/kjp.2008.46.4.293. View

20.

Tenter A . Toxoplasma gondii in animals used for human consumption. Mem Inst Oswaldo Cruz. 2009; 104(2):364-9. DOI: 10.1590/s0074-02762009000200033. View